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current attention is paid to improving chondrogenic differentiation capacity; unfortunately,
the potential chondrogenic hypertrophy of differentiated cells is largely overlooked. Conse-
quently, the engineered tissue is actually a transient cartilage rather than a permanent one.
The development of hypertrophic cartilage ends with the onset of endochondral bone forma-
tion which has inferior mechanical properties. In this review, current strategies for inhibition
of chondrogenic hypertrophy are comprehensively summarized; the impact of cell source op-
tions is discussed; and potential mechanisms underlying these strategies are also categorized.
This paper aims to provide guidelines for the prevention of hypertrophy in the regeneration of
cartilage tissue. This knowledge may also facilitate the retardation of osteophytes in the treat-
ment of osteoarthritis.
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Articular cartilage is an avascular and aneural translucent
tissue that functions by resisting compression, preventing
adjacent bone contact, and maintaining a low-friction
surface for joint articulation. Anatomically, normal artic-
ular cartilage is composed of four main zones: the super-
ficial zone, the middle zone, the deep zone, and the zone
with calcified cartilage; a tide-mark separates articular
cartilage from subchondral bone.1 Articular cartilage is
composed of chondrocytes and extracellular matrix (ECM).
Cartilaginous ECM contains collagen type II (COLII), non-
collagenous proteins, and proteoglycans, such as aggrecan
(AGC), that have sulfated glycosaminoglycans (GAGs) that
absorb water. Chondrocytes are responsible for the gener-
ation and maintenance of the ECM and are the sole,
differentiated cellular resident of articular cartilage.
Articular cartilage has a relatively high incidence of
damage and deterioration from common trauma such as
sports injury and diseases such as osteoarthritis.2 Due to
the avascular nature of articular cartilage, the progenitor
cells in blood and bone marrow are inaccessible to the
injured cartilage and the chondrocytes cannot move to the
injured cartilage and generate ECM to repair the damaged
cartilage; consequently, articular cartilage is weak in self-
repairing and generally ends up with a fibrous repair tis-
sue (fibrocartilage) which lacks the biomechanical charac-
teristics necessary to withstand compressive stress during
articulation. This fibrocartilage generally deteriorates over
time, resulting in a return of the original symptoms and
occasional progression to osteoarthritis.3
Taking the knee joint as an example, current methods
for treatment of articular cartilage lesions4 consist of (1)
Palliative Strategies, such as physiotherapy, weight loss,
and systemic pain relief medications; (2) Non-reparative,
Non-restorative Strategies, such as debridement, chondral
shaving, and knee joint lavage; (3) Reparative Strategies,
such as arthroscopic abrasion arthroplasty, microfracture,
and subchondral drilling; (4) Restorative Strategies, such as
high tibial osteotomy, unicompartmental knee arthroplasty,
and total knee arthroplasty; and (5) Transplantation Stra-
tegies, such as osteochondral transplantation (osteochon-
dral grafting), mosaicplasty, and autologous chondrocyte
transplantation (ACT). Although these methods can relieve
the pain to a certain extent and improve knee joint func-
tion, the effect is controversial.5
Of the above methods, ACT shows promise in clinical
follow-up. This approach consists of harvesting chondrocytes
from the non-weight bearing healthy area of articular
cartilage followed by cell culturing for approximately 6
weeks and then transplantation of the cultured cells during
open surgery. Despite the advantages of reducing the risk of
immunological rejection and transmissible disease, ACT has
many disadvantages including donor-site morbidity, the
requirement for two surgeries, possible leakage of chon-
drocytes from the recipient site, uneven distribution of the
cells in the defect, chondrocyte dedifferentiation in mono-
layer culture, long recovery timeafter operation, andfinally,
periosteal hypertrophy.6 The loss of chondrocyte phenotype
prior to utilization in implantation is of grave concern for
cartilage engineering and regeneration.Unlike chondrocytes, mesenchymal stem cells (MSCs) are
becoming a promising cell source for cartilage regeneration
due to in vitro expansion without running the risk of losing
their phenotype; however, MSCs tend to simultaneously
acquire hypertrophic properties during chondrogenic in-
duction, indicating the possibility of further differentiation
toward endochondral bone formation.7,8 It is becoming
crucial to systematically assess current strategies for
minimizing hypertrophy of chondrogenically differentiated
cells to provide a high-quality cartilage tissue for clinical
defect repair. A previous review covered molecular and
biophysical mechanisms regulating hypertrophic differen-
tiation in chondrocytes and MSCs9; this review will focus on
strategies for preventing chondrogenic hypertrophy,
including some new findings, such as the impact of different
MSC sources and culture substrates. Potential mechanisms
underlying the above strategies will also be delineated.Definition and characterization of
chondrogenic hypertrophy
Chondrogenic hypertrophy is marked by a more than 10-fold
increase in cell volume and ECM structural remodeling.10
Cell volume expansion affects cell function.11 The explo-
sive increase in the volume of hypertrophic chondrocytes
involves changes in intracellular and extracellular osmo-
larity, ECM degradation around the cell, and an increase in
the amount of organelles per cell.12 Osmotic swelling has
been shown stereologically to be responsible for most of
the cell volume increase. Swelling can be the result of
either an increase in cytoplasmic concentration or a
decrease in extracellular osmolarity followed by aquaporin-
mediated movement of water to re-establish iso-osmotic
conditions.13 Of all the ECM molecules, AGC is the prime
contributor to the osmotic pressure generated in cartilage,
both due to its abundance and its high negative fixed
charge. It is not completely understood if expression of
terminal markers results in increased cell volume or vice
versa.
Chondrocyte hypertrophic differentiation is the gradual
development process from chondrogenic differentiation to
cartilage mineralization, which is characterized by a series
of markers; each of these markers has its own function in
the process of cartilage mineralization.14 For example, the
transcription factors, runt-related transcription factor 2
(RUNX2) and myocyte enhancer factor-2C (MEF2C), drive
the expression of terminal differentiation markers,
including matrix metalloproteinase 13 (MMP13),9 collagen
type X (COLX),15 Indian hedgehog (IHH),16 alkaline phos-
phatase (ALP), and vascular endothelial growth factor
(VEGF),8,17 which all functionally contribute to endochon-
dral ossification. Secreted MMP13 degrades COLII and AGC,
key ECM components of functional cartilage18; COLX serves
as a framework for subsequent calcification through matrix
vesicles (MV)19; ALP hydrolyses pyrophosphate (PPi) to
inorganic phosphate (Pi) which, in the presence of calcium,
forms hydroxyapatite20; and IHH induces the proliferation
of non-hypertrophic chondrocytes.21
Calcification of cartilage ECM originates at MV.22 ECM
mineralization to endochondral bone formation consists of
78 S. Chen et al.three steps (Fig. 1): (1) Hydroxyapatite crystals are formed
inside the MV; (2) Hydroxyapatite crystals penetrate MV
into the ECM; and (3) Endochondral ossification. The final
stages of endochondral ossification, including degradation
of the calcified matrix, VEGF-mediated vascular invasion of
the calcified zone, and deposition of osteoid on the calci-
fied trabeculae by osteoblasts, are all under the control of
MMPs.23 MMP is indispensable for the development of MV
and it can calcify the growth plate; finally, calcification is
substituted by endochondral bone. MMP13 binding to the
MV membrane and cooperating with MMP9 could promote
the release of VEGF in apoptotic chondrocytes, furtherFigure 1 ECM mineralization process: (1) Hydroxyapatite
crystals are formed inside the MV (gray shading) when the
concentration of calcium ion (influx through annexinII/V/VI
calcium ion channels) and Pi [produced by the hydrolysis of
Pcho and PEA via PHOSPHO1236,237 and transferred into the MV
by type-III Naþ/Pi cotransporter238,239 exceeds the solubility
values.20,238 (2) Hydroxyapatite crystals penetrate MV into the
ECM (light grey shading). ATP, in the presence of nucleotide
NPP1,240 can generate PPi which would in return inhibit the
formation of hydroxyapatite.241 Pi could be produced through
TNAP hydrolyzation of PPi238 and ALP dephosphorylation of PPi,
promoting the formation of hydroxyapatite. PPi and Pi have
antagonistic effects on the mineralization process.20,242
Abbreviation: ALP: alkaline phosphatase; ATP: adenosine
triphosphate; ECM: extracellular matrix; MV: matrix vesicles;
NPP1: nucleotide pyrophosphatase phosphodiesterase 1; Pcho:
phosphatidyl choline; PEA: phosphatidylethanolamine; PHOS-
PHO1: phosphoethanolamine/phosphocholine phosphatase; Pi:
phosphatidylinositol; PPi: extracellular inorganic pyrophos-
phate; TNAP: tissue non-specific alkaline phosphatase.accelerating the formation of vascularity in the growth
plate.24
Impact by cell sources chosen
Adult MSCs can differentiate into osteoblasts, adipocytes,
muscle, and chondrocytes and are a promising cell source
for tissue regeneration.25 Recent evidence indicates that
great variability in differentiation capacity exists among
tissue-specific stem cells,26 which might provide a theoretic
foundation in regenerating a high-quality hyaline cartilage
with minimum potential for hypertrophy.27
Articular chondrocytes
Articular chondrocytes are the earliest used cell sources for
ACT.28 Due to limited availability, harvested chondrocytes
need to be expanded in monolayer to obtain sufficient cells
before implantation. However, monolayer expansion leads
to a rapid chondrocyte dedifferentiation and causes loss of
phenotype29 despite the limited restoration of chondro-
genic properties of articular chondrocytes using growth
factors and/or three dimensional (3D) culture.30e32 Dedif-
ferentiated chondrocytes mostly become fibrous cartilage
rather than hyaline cartilage33 with inferior biomechanical
properties,34,35 thus limiting the application of articular
chondrocytes in cartilage repair.
Articular cartilage progenitor cells
Articular cartilage progenitor cells (ACPCs) usually exist in
one third of the superficial zone of articular cartilage.36e39
Recent findings show that ACPCs also exist in two thirds of
the deep zone; the cell number in the deep zone is inferior
to that in the superficial zone, but the chondrogenic and
osteogenic differentiation capabilities are superior.40
McCarthy and colleagues found that both ACPCs and bone
marrow stromal cells (BMSCs) could be induced for chon-
drogenic differentiation while COLX, RUNX2, and matrilin-1
existed only in the differentiated cells from BMSCs.41 ACPCs
may therefore be considered superior to BMSCs in produc-
ing cartilage capable of functional repair despite a report
showing ACPCs with inferior capability of producing carti-
laginous matrix compared to articular chondrocytes.42
ACPCs isolated from the healthy area of articular carti-
lage could cause donor-site morbidity.43 When articular
cartilage is injured severely, ACPCs begin to proliferate and
migrate to the damaged site and act as alarmins promoting
the development of inflammation44 while articular chon-
drocytes remain in a stationary state.45 The research on
ACPCs is still in the early stage and needs further investi-
gation to elucidate its role in cartilage regeneration.
Embryonic stem cells
Embryonic stem cells (ESCs) have the ability of infinite
proliferation and self-renewal as well as differentiating into
all kinds of human cells.46 The use of human ESCs to replace
damaged cells and tissues is promising for cartilage tissue
engineering in the future. However, in vitro chondrogenic
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trophically differentiate.47 Complex ethical and legal
questions as a result of the research needed to develop
these cell-replacement therapies restrict the use of ESCs in
research and clinical settings.Mesenchymal stem cells
Mesenchymal stem cells are promising candidate cells for
cartilage tissue engineering. High expression of cartilage
hypertrophic markers such as COLX, MMP13, and phos-
phorylated ALP by BMSCs undergoing chondrogenic induc-
tion were observed in in vitro pellet culture.8 Like BMSCs,
chondrogenesis of adipose-derived stem cells (ADSCs) was
also associated with hypertrophy according to premature
COLX expression and up-regulation of ALP activity as well as
in vivo calcification of spheroids after ectopic trans-
plantation in SCID mice.7
Recent evidence indicates that tissue-specific stem cells
exhibit lineage-specific differentiation potential (Fig. 2).26
Compared to MSCs from adipose, bone marrow, andFigure 2 Adult stem cells can be derived from various tissues i
ulations can be expanded in vitro and induced to undergo lineage-s
myogenesis (M), or adipogenesis (A). Although the cells may appe
identical. From the data presented in the paper entitled “Impact o
focus on the musculoskeletal system”,26 the efficacy of adult stem c
type of resident tissue from which they are harvested. In the heat
from low differentiation (blue) to high differentiation (red).muscle, synovium-derived stem cells (SDSCs) display supe-
rior chondrogenic capacity with a limited potential toward
hypertrophy.27 The lineage-specific differentiation ability
of MSCs is also influenced by matrix microenvironment
deposited by tissue-specific stem cells. For example,
decellularized matrix deposited by SDSCs enhanced
expanded SDSCs’ chondrogenic potential rather than oste-
ogenic capacity,48 while decellularized matrix deposited by
BMSCs promoted expanded BMSCs’ endochondral bone
formation.49
Besides various site-dependent MSCs, cell composition
also plays a critical role in MSC-based cartilage engineering
and regeneration. BMSCs are multi-lineage potential non-
hematopoietic cells, accounting for only a small percentage
of nucleated cells in bone marrow.50 Hematopoietic cells
could yield short-term selected (STS) cells; passaging en-
riches more primitive, uniformly Sca-1 expressing, long-
term selected (LTS) cells. In STS cells, chondrogenesis
progressed rapidly to terminal differentiation while LTS
cells differentiated at a slower rate with no hypertrophy.
These data indicate the impact of stromal cell composition
on the chondrogenic differentiation profile, which is ann the body. These viable and undifferentiated stem cell pop-
pecific differentiation for chondrogenesis (C), osteogenesis (O),
ar similar in morphology upon harvest, they are anything but
f tissue-specific stem cells on lineage-specific differentiation: a
ells in lineage-specific differentiation is greatly affected by the
map, the differentiation capacity is visualized by color ranging
80 S. Chen et al.important aspect to be considered when developing MSC-
based cartilage repair technologies.51Strategies for inhibition of chondrogenic
hypertrophy
Specific intervention
Current evidence indicates that chondrogenic hypertrophy
can be prevented with interventions (Table 1) at a protein
level, such as parathyroid hormone-related peptide
(PTHrP),52 transforming growth factor beta1 (TGF-b1),53
MMP13 inhibitor,54 and extracellular signal-regulated pro-
tein kinases 1 and 2 (Erk1/2) inhibitor,55 and at a gene
level, such as NK3 homeobox 2 (Nkx3.2),56 histone deace-
tylase 4 (HDAC4),57 and Chondromodulin 1 (ChM1).58,59
Protein-level intervention
PTHrP. During the development of cartilage, PTHrP,
belonging to the family of parathyroid hormones (PTHs),
maintained chondrocytes in a proliferative state and
inhibited their terminal differentiation into hypertrophic
chondrocytes.60 The addition of PTHrP in a dose-
dependent fashion increased DNA and GAG contents in
the pellets of both human BMSCs and ADSCs with down-Table 1 Specific intervention to prevent hypertrophy
during chondrogenic differentiation.
Hypertrophy
inhibitors
Target molecules
Protein level PTHrP Nkx3.2/PKC/cAMP/CaMKII
TGF-b Smad 2/3 or Smad1/5/8
BMP-4/7/13 Bapx1/Nkx3.2
GG86/2 MMP13
Dorsomorphin BMPIR
PD98059 Erk1/2
NSC23766 Rac1
FK506 Calcineurin
Gene level Nkx3.2 RUNX2
SOX9 b-catenin/PTHrP/RUNX2
Smad6 Smad1/5/8
HDAC4 Runx2/MEF2C
ChM1 p21
sFlt-1 VEGF
C-1-1 RUNX2/COLX/ALP
Abbreviation: ALP: alkaline phosphatase; Bapx1: bagpipe ho-
meobox homolog 1; BMP: bone morphogenetic protein; BMPIR:
bone morphogenetic protein receptor I; cAMP: cyclic adenosine
monophosphate; CaMKII: Ca2þ/calmodulin-dependent protein
kinase II; ChM1: Chondromodulin 1; COLX: type X collagen;
Erk1/2: extracellular regulated protein kinases 1/2; HDAC4:
histone deacetylase-4; MEF2C: myocyte-specific enhancer fac-
tor 2C; MMP13: matrix metalloproteinase 13; Nkx3.2: NK3 ho-
meobox 2; PKC: protein kinase C; PTHrP: parathyroid hormone-
related peptide; Rac1: Ras-related C3 botulinum toxin substrate
1; RUNX2: runt-related transcription factor 2; sFlt-1: soluble
Flt-1; Smad: mothers against decapentaplegic homolog
(Drosophila); SOX9: sex determining region Y-type high mobility
group box 9; TGF-b1: transforming growth factor beta 1; VEGF:
vascular endothelial growth factor.regulation of COL10A1 and RUNX2 and up-regulation of
SRY (sex determining region Y)-box 9 (SOX9) and
COL2A1, suggesting PTHrP could promote chondrogenesis
and suppress hypertrophy during in vitro
chondrogenesis.61 Mueller and coworkers found that
PTHrP(1e40) treatment reduced ALP expression in
human BMSC pellets cultured under standard
chondrogenic conditions in a dose-dependent manner;
however, when cultured under hypertrophy-enhancing
conditions, PTHrP(1e40) could not diminish the induced
enhancement of hypertrophy in the MSC pellets.52
Kafienah and colleagues also found that the inclusion of
PTHrP at a dose of 1 mM or 10 mM in chondrogenic
induction medium resulted in significant suppression of
COL10A1 and ALP activity in cartilage constructs
engineered from BMSCs of patients with osteoarthritis.62
Of four PTHrP isoforms (1e34, 1e86, 7e34, and
107e139), Lee and Im found that PTHrP(1e34) most
significantly enhanced chondrogenesis and suppressed
hypertrophy in human BMSCs, supporting its use for
cartilage tissue engineering.63
TGF-b. Shintani and coworkers reported that TGF-b1
enhanced the bone morphogenetic protein 2 (BMP-2)-
induced chondrogenesis of bovine synovial explants,
improved the hyaline-like properties of the neocartilage,
and arrested the downstream differentiation of cells at an
early stage of hypertrophy.53 Mello and Tuan found that
TGF-b1 stimulated limb mesenchymal cell proliferation
and suppressed hypertrophy from chick embryos, while
the thyroid hormone triiodothyronine stimulated
hypertrophy and apoptosis.64 Intriguingly, Cals and
coworkers found that human BMSC pellets cultured with
TGF-b1 had significantly less mineralization than pellets
cultured with TGF-b3.65 Consistent with this finding, Pei
and colleagues found that, despite a comparable
chondrogenic capacity during in vitro induction, the
supplementation of TGF-b3 up-regulated COL10A1 and
ALP in porcine SDSC pellets compared to TGF-b1.66
However, Mueller and coworkers did not observe
significant TGF-b subtype-dependent differences in
suppressing hypertrophy in chondrogenic induction of
human BMSCs.67 Interestingly, TGF-b-depletion during
expansion improved the re-differentiation capacity of
chondrocytes and inhibited hypertrophy68 while TGF-b1
administration during expansion of human articular
chondrocytes in a serum-free medium redirected cell
phenotype toward hypertrophy.69
BMP-4/7/13 and Dorsomorphin. Belonging to the super-
family of TGF-b, BMP enhanced the TGF-b-induced chon-
drogenesis of MSCs.70 BMP-4 promoted MSC chondrogenic
differentiation while suppressing hypertrophy.71 Caron and
coworkers found that BMP-2 acted as a specific inducer of
chondrocyte hypertrophy while BMP-7 appeared to
increase or maintain chondrogenic potential and prevent
chondrocyte hypertrophy; bagpipe homeobox homolog 1
(Bapx1)/Nkx3.2 was involved in the BMP-7 mediated
suppression of chondrocyte hypertrophy in ATDC5 cells
(clonal mouse embryonal carcinoma cells).72 BMP-13
inhibited osteogenic differentiation of human BMSCs
in vitro.73 Those studies indicated that BMP-4/7/13 can
Prevention of chondrogenic hypertrophy 81increase or maintain chondrogenic potential and prevent
chondrocyte hypertrophy. Terminal differentiation and
mineralization of chondrocytes can be regulated by the
Smad1/5/8 pathway.74e76 Yu and colleagues found that
Dorsomorphin inhibited the BMP type I receptors activin
receptor-like kinase 2 (ALK-2), ALK-3, and ALK-6 and thus
blocked BMP-mediated Smad1/5/8 phosphorylation.77
MMP13 inhibitor. As one of the hypertrophic markers,
proteolysis involving MMP13 was required for chondrocyte
differentiation that occurs as part of growth plate devel-
opment and was associated with matrix mineralization.78
Bertram and coworkers found that broad spectrum pan-
MMP inhibitors suppressed proteoglycan deposition, COLII
and COLX staining, ALP activity, and reduced SOX9 and
COL2A1 expression in a dose-dependent fashion; a
selective MMP13 inhibitor GG86/2 allowed chondrogenesis
and showed only weak effects on ALP activity, indicating
that, in future therapeutic applications of diseased joints,
the tested MMP13-specific inhibitor GG86/2 promises
suppression of COLII degradation without imposing a risk
of impairment of MSC-driven regeneration processes.54
Erk1/2 inhibitor. Erk1/2 signaling, one of the mitogen-
activated protein kinase (MAPK) pathways, increased
chondrogenic hypertrophy.79 Kim and Im found that the
addition of PD98059, an Erk1/2 inhibitor, in chondrogenic
medium suppressed hypertrophy and promoted
chondrogenesis of human MSCs in a pellet culture
system.80 Furthermore, the in vitro culture results
showed that the PD98059-impregated poly(lactic-co-
glycolic acid) (PLGA) scaffold is more effective in
suppressing hypertrophy than the TGF-b2-immobilized
scaffold while both scaffolds enhance chondrogenesis
from human BMSCs. After 10 weeks of in vivo
implantation in rabbits, osteochondral defects were
successfully repaired in both PD98059-impregnated and
TGF-b2-immobilized scaffolds seeded with rabbit BMSCs
when evaluated grossly and microscopically. However,
COLX was not observed from regenerated cartilage in
PD98059-impregnated scaffold, whereas it was detected
around chondrocytes in the TGF-b2-impregnated
scaffolds. These results suggested that the use of the
PD98059-impregnated scaffold led to articular cartilage
regeneration of better quality and prevented hypertrophy
when implanted in osteochondral defects.55
Rac1 inhibitor. Rac1 belongs to the Rho family of small
GTPases and can promote chondrocyte hypertrophy within
the growth plate.81 Rac1 inhibitor was also reported to
decrease the expression of COL10A1 in human ADSCs.82
Activated Rac1 promoted expression of MMP13, a
disintegrin and metalloproteinase with thrombospondin
motifs 5 (ADAMTS5), and COLX in chondrocytes, and
accelerated osteoarthritis progression while inhibition of
Rac1 activity by NSC23766 delayed osteoarthritis
development.83 Furthermore, TGF-b3 promoted ADSC
chondrogenic differentiation and NSC23766 prevented
differentiated cells from hypertrophy in vitro. The
combination of ADSCs, TGF-b3, and NSC23766 promoted
the quality of osteochondral defect repair in rats withmuch less chondrocyte hypertrophy and significantly
higher International Cartilage Repair Society macroscopic
and microscopic scores.84
FK506. FK506 (Tacrolimus) exerts its immunosuppressive
effect via a common mechanism, calcineurin inhibition,
after binding to intracellular proteins FK506-binding
protein (FKBP). FK506 was found to induce chondrogenic
differentiation of ATDC5 cells in a concentration-
dependent manner (0.1e1000 ng/ml).85 van der Windt
and colleagues found that inhibition of calcineurin
activity by FK506 increased the expression of
chondrogenic markers via endogenous TGF-b1 production
in human articular chondrocytes.86 Furthermore, FK506 at
physiologic tonicity (380 mOsm) exerted a superior effect
compared to the physiologic tonicity or FK-506 alone,
increasing anabolic markers while suppressing
hypertrophic and catabolic markers.87
Gene-level intervention
Nkx3.2. Nkx3.2 is a transcription factor inhibitor promoting
chondrogenesis88 which acts as a negative regulator of
chondrocyte maturation in vivo.89 Lengner and colleagues
found that transfection of Nkx3.2 into pluripotent
C3H10T1/2 cells showed dose-responsive repression of the
RUNX2 promoter. Bypassing RUNX2 repression by
adenoviral-mediated introduction of RUNX2 into C3H10T1/
2 cells prevented the induction of chondrogenesis, but
could not reverse the chondrogenic phenotype once it was
initiated, as evidenced by SOX9 and COL2A1 expression and
ECM deposition. These results suggest that RUNX2 is a
direct transcriptional target of Nkx3.2 and that repression
of RUNX2 at the onset of chondrogenesis is a prerequisite
for the activation of a chondrocyte-specific program of
gene expression.56 RUNX2 is a critical link in BMP-2-
mediated initiation of mesenchymal chondrogenesis that
results in activation of SOX9 at least in part through the
Nkx3.2-dependent repression of RUNX2.56
SOX9 and/or SOX5/SOX6. Sox proteins are necessary in the
process of cartilage formation. SOX9 mutation can cause
serious cartilage dysplasia, in terms of campomelic
dysplasia.90 SOX5 and SOX6 knockout also can cause serious
cartilage dysplasia, leading to death at birth in a mouse
model.91 Overexpression of SOX9 promoted the ability for
chondrogenesis in mouse BMSCs.92 The SOX5, SOX6, and
SOX9 combination (the SOX trio) successfully induced
chondrocyte differentiation of mouse ESCs.93 Moreover,
Ikeda and coauthors found that, among various
combinations examined, only the SOX trio successfully
induced chondrocyte differentiation in all cell types
tested, including nonchondrogenic types, and the
induction occurred regardless of the culture system used
(monolayer, spheroid, and 3D). Contrary to the
conventional chondrogenic techniques, the SOX trio
suppressed hypertrophic and osteogenic differentiation at
the same time.94 Venkatesan and coworkers found that
recombinant adeno-associated virus (rAAV)-FLAG-hSOX9
delivery in human BMSCs strongly enhanced chondrogenic
differentiation and reduced the levels of markers of
hypertrophy and terminal and osteogenic/adipogenic
82 S. Chen et al.differentiation. These effects were accompanied with
decreased levels of b-catenin (an indicator of osteoblast
lineage differentiation) and enhanced PTHrP expression
via SOX9 treatment.95
SMAD6. Smad6 and Smad ubiquitin regulatory factor 1
(Smurf1) blocked the signal transduction of the BMP-
Smad1/5/8 pathway.96,97 SMAD6 transgenic mice showed
postnatal dwarfism with osteopenia and inhibition of
Smad1/5/8 phosphorylation in chondrocytes.96 In cultured
human articular chondrocytes, stimulation with
interleukin 1b (IL-1b) showed up-regulation of SMAD7,
whereas SMAD6, aggrecan (ACAN ), and COL2A1 were
down-regulated,98 suggesting a potentially important role
of IL-1b signaling in chondrocytes via indirect influencing
of the BMP/TGF-b signaling cascade. Histological analysis
of appendicular bones revealed delayed onset of
hypertrophic differentiation and mineralization at
midgestation in SMAD6/ mice.99 By late gestation,
however, an expanded hypertrophic zone associated with
an increased pool of proliferating cells undergoing
hypertrophy was evident in SMAD6 mutant growth plates.
Loss of SMAD6 in mice led to defects in both axial and
appendicular skeletal development.99 Overall, those
results show that Smad6 is required to limit BMP signaling
during endochondral bone formation.
HDAC4. HDACs modulate cell growth and differentiation
by governing chromatin structure and repressing the ac-
tivity of specific transcription factors.100,101 HDAC4-null
mice display premature ossification of developing bones
due to ectopic and early onset chondrocyte hypertrophy,
mimicking the phenotype that results from constitutive
RUNX2 expression in chondrocytes. Conversely,
overexpression of HDAC4 in proliferating chondrocytes
in vivo inhibited chondrocyte hypertrophy and
differentiation, mimicking a RUNX2 loss-of-function
phenotype.102 These results establish HDAC4 as a central
regulator of chondrocyte hypertrophy and skeletogenesis
and suggest general roles for class II HDACs in the control
of cellular hypertrophy. Similarly, Pei and coauthors found
that, in the presence of TGF-b1, adenovirus-mediated
HDAC4 transduction in porcine SDSCs sped up and
maintained a high level of chondrogenesis while down-
regulating COL10A1 expression.57 Shimizu and coworkers
found that HDAC4 interacted with RUNX2, bound the
MMP13 promoter, and suppressed MMP13 gene
transcription in the rat osteoblastic cell line, UMR 106-01.
PTH induces the rapid cyclic adenosine monophosphate
(cAMP)-dependent protein kinase-dependent release of
HDAC4 from the MMP13 promoter and subsequent
transcription of MMP13. Knock-out of HDAC4 either by
small interfering RNA (siRNA) in vitro or by gene deletion
in vivo led to an increase in MMP13 expression;
overexpression of HDAC4 decreased the PTH induction of
MMP13, indicating that HDAC4 represses MMP13 gene
transcription in bone.103
Chondromodulin 1/soluble Flt-1. ChM1 is significant in
articular cartilage and could induce the chondrocyte
phenotype and inhibit the invasion of vessel structures.104
Klinger and colleagues found that transplantation ofporcine osteochondral progenitor cells infected with AAV-
ChM1 to cartilage lesions in the knee joints of miniature
pigs that were treated by the microfracture technique
stabilized the chondrocyte phenotype by supporting
chondrogenesis but inhibiting chondrocyte hypertrophy
and endochondral ossification.105 The underlying
mechanism is unclear; some studies indicated that ChM1
promotes expression of the cell cycle inhibitor p21WAF1/
Cip1,106 preventing expression of ALP and COL10A1.58,59
VEGF increased the BMP-4-induced endochondral bone
formation of muscle-derived stem cells (MDSCs) in vitro.107
The soluble Flt-1 (sFlt1) gene, a VEGF antagonist, delayed
the development of mouse osteoarthritis.108 Kubo and co-
workers found that sFlt-1 gene therapy improved BMP-4-
and TGF-b3-induced in vitro chondrogenesis of MDSCs and
promoted the persistence of articular cartilage repair by
preventing vascularization and bone invasion into the
repaired articular cartilage.109 Matsumoto and colleagues
also reported that, after intraarticular injection of stem
cells for cartilage repair in an immunodeficient rat osteo-
arthritis model, a combination of sFlt-1- and BMP-4-
transduced MDSCs demonstrated better repair without
osteophyte formation macroscopically and histologically
when compared with a combination of VEGF- and BMP-4-
transduced MDSCs or with BMP-4-transduced MDSCs
alone.110 However, some reports also indicated that VEGF is
a necessary survival factor for stem cells and chondrocytes
in the process of cartilage development. In VEGF knockout
mice, a lot of chondrocytes died in the epiphyseal region
during the process of cartilage development.111,112
ERG/C-1-1. The ETS-related gene (ERG) belongs to the
family of erythroblast transformation-specific (ETS)
transcription factors.113 Iwamoto and coworkers found
that, during limb development, C-1-1 and ch-ERG had
diverse biological properties and distinct expression
patterns. Virally driven expression of C-1-1 maintained
chondrocytes in a stable and immature phenotype,
blocked their maturation into hypertrophic cells, and
prevented the replacement of cartilage with bone. In
contrast, virally driven expression of ch-ERG significantly
stimulated chondrocyte maturation in culture, as
indicated by increases in ALP activity and deposition of a
mineralized matrix; however, it had modest effects
in vivo. Growth of articular chondrocytes in culture was
accompanied by decreasing C-1-1 expression after several
passages, while expression of hypertrophic markers
increased. Expression of C-1-1 in cultured chondrocytes
inhibited cell hypertrophy, ALP activity, and cartilage
matrix mineralization. In contrast, over-expression of ch-
ERG promoted chondrocyte maturation and
mineralization.114 Those findings suggest that C-1-1 plays
a crucial role in the development process of cartilage
formation and is important for steering the cells toward
alternative developmental paths in the epiphyseal region;
it also makes chondrocytes in the epiphyseal region
acquire a permanent articular chondrocyte phenotype.
Co-culture
The use of a co-culture system of articular chondrocytes
and MSCs could enhance chondrogenesis and suppress
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colleagues found that human BMSCs co-cultured with pri-
mary osteoarthritic chondrocytes underwent chondrogenic
differentiation even in the absence of growth factors;
however, the same effect could not be replicated using
osteoarthritic chondrocyte-conditioned medium or
expanded cells. Additionally, the co-culture environment
down-regulated hypertrophic differentiation of human
BMSCs.117 Bian and coworkers found that mixed cell pop-
ulations (human BMSCs and human articular chondrocytes)
encapsulated in hydrogels exhibited significantly higher
Young’s moduli, dynamic moduli, GAG levels, and collagen
content than did constructs seeded with only BMSCs or
chondrocytes. In addition, the deposition of COLX was
significantly lower in the co-culture constructs than in the
constructs seeded with BMSCs alone.118
Articular chondrocyte-derived soluble factors and direct
co-culture are potent means of improving chondrogenesis
and suppressing the hypertrophic development of MSCs.
PTHrP secreted by chondrocytes is an important candidate
soluble factor involved in this effect.119,120 Two distinct cell
types (human BMSCs and rabbit articular chondrocytes)
were encapsulated in alginate hydrogels singly or in various
ratios and cultured under chondrogenic conditions; Mo and
coworkers found that newly synthesized cartilaginous ECM
and COL2A1 were up-regulated with greater human BMSC
ratios and longer culture periods. However, a specific
COL2A1 human gene probe was found only in single human
BMSC groups and was absent in all co-culture groups, which
indicated that the enhanced cartilaginous phenotype orig-
inated from the co-cultured rabbit chondrocytes.121 Bovine
articular chondrocytes co-cultured with BMSCs also resulted
in redifferentiation of passaged chondrocytes and the tro-
phic effect of MSCs may significantly increase the chon-
drogenic potential of articular chondrocytes.122 Those
studies indicated that both MSCs and articular chondrocytes
stabilized the chondrocyte phenotype. MSCs drive chon-
drocytes to synthesize cartilaginous ECM; chondrocytes also
inhibit or minimize the hypertrophy of chondrogenic MSCs.Culture substrates
Culture substrates can be synthetic material, purified single
matrix component, or comprehensive decellularized matrix
from mature tissue or grown cells. Cell phenotype, adhe-
sion, migration, proliferation, and differentiation can be
affected by culture substrates, such as ECM components
and structure.123
Nitrogen-rich plasma polymer
One of the most important properties of MSCs is adherent
growth. The capability for adhesion of stem cells can be
enhanced by nitrogen (N)-rich plasma polymer layers
(PPE:N).124 Petit and colleagues found that PPE:N sup-
pressed COL10A1 in fetal bovine growth plate chondrocytes
but had no significant effect on COL2A1, ACAN, MMP13, and
cyclin B2 (CCNB2) levels,125 indicating that PPE:N is bene-
ficial for MSC chondrogenesis. Similarly, Mwale and co-
workers found that PPE:N almost completely suppressed
the expression not only of COL10A1, but also of osteogenic
marker genes such as ALP, bone sialoprotein (BSP), andosteocalcin (BGLAP) in human BMSCs. In contrast, neither
ACAN nor COL1A2 expression was significantly affected.126
Rampersad and coworkers further confirmed the potential
of two different types of PPE:N surfaces (low-pressure-
PPE:N [L-PPE:N] and high-pressure-PPE:N [H-PPE:N]) in
suppressing COL10A1 expression, more so on the latter.
Interestingly, when human BMSCs were transferred to pel-
let cultures, the expression level of COL10A1 was further
decreased by preincubation on H-PPE:N, suggesting that
these kinds of coatings show promise for tissue engineering
of cartilage and disc tissues.127
Chondroitin sulfate
Chondroitin sulfate (CS), a chemical that is normally found
in articular cartilage, has been widely used in cartilage
tissue engineering.128e130 Varghese and colleagues found
that the aggregation of goat BMSCs in poly(ethylene glycol)
(PEG)/CS hydrogels resulted in an enhancement of chon-
drogenic genes and matrix production and a significant
down-regulation of COLX expression compared to control
PEG hydrogels containing no CS-moieties.131 Similarly, a 3D
alginate microbead platform was coated with cartilaginous
ECM components hyaluronic acid, CS, and COLII to emulate
an in vivo chondrogenic microenvironment for the differ-
entiation of BMSCs; Wu and coworkers found that CS- and
COLII-coated microbeads enhanced the chondrogenic dif-
ferentiation of human BMSCs. In addition, COLII-coated
microbeads resulted in hypertrophic maturation of the
differentiated chondrocytes, similar to conventional pellet
culture, while CS-coated microbeads were able to retain
the pre-hypertrophy state of the differentiated cells.132
Those findings demonstrated that CS coatings are benefi-
cial to induce MSCs to differentiate into chondrocytes and
prevent hypertrophy.
Decellularized matrix
ECM, an indispensable niche for stem cells in vivo, not only
provides support scaffold, but also participates in the
regulation of self-renewal, proliferation, and differentia-
tion of stem cells.133 Decellularization of natural ECM,
eliminating the cells and antigen composition, can avoid
disease transmission, reduce inflammation and immune
response, and maintain the integrity of ECM.134 The ad-
vantages of using ECM in cartilage engineering and regen-
eration include not only the formation of functional specific
tissue dependent on several conditions, such as cytokines
inside ECM and unique surface anatomical features,135,136
but also the in vitro microenvironment for stem cell reju-
venation during in vitro expansion.48,49,137,138
Cartilage matrix. A porous scaffold derived from adult
porcine articular cartilage has the ability to induce chon-
drogenic differentiation of human ADSCs without exoge-
nous growth factors, with significant synthesis and
accumulation of ECM macromolecules, and with the
development of mechanical properties approaching those
of native cartilage.139 In a further study, acellular cartilage
matrix (ACM) powders and human SDSCs were mixed into
collagen gel for in vitro culture. The data showed that
ACM powders had the potential of promoting COL2A1
expression in an environment with no growth factors; a
synergistic effect between ACM powders and
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of engineered cartilage and reduction of hypertrophy in
chondrogenesis of SDSCs.140
Stem cell matrix. He and coworkers found that decellu-
larized matrix deposited by stem cells (DSCM) could provide
a cell expansion system for the rejuvenation of porcine
SDSCs, in terms of “tiny and spindle shaped typical stem
cell morphology”, “higher cell yields (about 44 times more
than those expanded on plastic flasks for two continuing
passages)”, and “high-quality cells (in subsequent 14-day
chondrogenic induction, ECM expanded SDSCs exhibited a
higher ratio of GAG to DNA than plastic expansion,
39.37  3.05 versus 5.19  1.11)”, despite the pellets
from the DSCM expanded SDSC group having half the level
of COL10A1.48 From the same laboratory, Li and Pei found
that both basic fibroblast growth factor (FGF2) and DSCM
could promote porcine SDSCs’ proliferation and
chondrogenic potential; however, in the subsequent
chondrogenic induction, DSCM expanded SDSCs yielded
pellets with significantly lower levels of COL10A1, ALP,
and MMP13 compared to FGF2 pretreated SDSCs.141
Chondrocyte matrix. A cell-derived ECM scaffold was
constructed using cultured porcine chondrocytes via a
freeze-drying method; Jin and colleagues demonstrated
its ability to promote cartilage formation both in vitro and
in vivo.142,143 From the same group, Choi and colleagues
evaluated the chondrogenic capacity of rabbit BMSCs
after growth on ECM scaffold deposited by porcine
chondrocytes and found that the ECM scaffold evoked
chondrogenic differentiation of BMSCs earlier and
produced more cartilaginous tissues than the polyglycolic
acid (PGA) scaffold. Next, BMSCs in each scaffold were
preconditioned with chondrogenic media in vitro for 1
week and implanted in the backs of nude mice for 6
weeks. The initially formed cartilaginous tissues turned
into bone matrix. This phenomenon progressed much
more rapidly in the PGA group than in the ECM group. In
the ECM group, the chondrogenic phenotypes of BMSCs
were also maintained longer than in the PGA group. The
loss of chondrogenic phenotypes was accompanied by the
calcification of matrix and hypertrophic changes by
immunohistochemistry for osteocalcin and COLI and COLX.
Blood vessel invasion took place more deeply and
intensively in the PGA group. These results suggested that
the ECM scaffold not only strongly supports chondrogenic
differentiation of rabbit MSCs, but also helps maintain its
phenotype in vivo.137Low oxygen
Cartilage is an avascular tissue and thus resides in a
microenvironment with reduced oxygen tension, indicating
that low oxygen might benefit in vitro chondrogenic dif-
ferentiation of MSCs. Expansion under hypoxia was re-
ported to enhance the preservation of “stemness”
properties and inhibit osteogenic potential of marrow-
isolated adult multilineage inducible (MIAMI) cells144 as
well as to increase chondrogenic differentiation of ADSCs
while suppressing hypertrophy.145,146 Similarly,chondrogenic induction in a low oxygen environment would
increase chondrogenic differentiation and suppress hyper-
trophy of MSCs cultured in both pellets and hydrogels used
in tissue engineering strategies.147 Hirao and coworkers
found that hypoxia promoted BMP2-induced GAG produc-
tion and suppressed ALP activity and mineralization of the
pluripotent mesenchymal cell line C3H10T1/2. Thus, hyp-
oxia promoted chondrocytic commitment rather than
osteoblastic differentiation. In the mouse embryo forelimb
organ culture, hypoxia increased cartilaginous matrix syn-
thesis. These effects were primarily mediated by p38 MAPK
activation, independent of SOX9. Hypoxia inhibited
COL10A1 expression via down-regulation of RUNX2 activity
by Smad suppression and HDAC4 activation. These findings
indicated that hypoxia promotes chondrocytic differentia-
tion and cartilage matrix synthesis and suppresses terminal
chondrocyte differentiation.148 Furthermore, Kawato and
colleagues demonstrated that Nkx3.2-dependent suppres-
sion of RUNX2 was a crucial factor in hypoxia-dependent
maintenance of chondrocyte identity.149Biomechanical stimulation
Cartilage cells live in an environment heavily influenced by
mechanical forces. Wong and coworkers found that cyclic
tension (shear stress) could up-regulate the expression of
RUNX2, MMP13, connective tissue growth factor (CTGF ),
COL10A1, and VEGF and down-regulate the expression of
the tissue inhibitor of metalloproteinase-1 (TIMP1) in
bovine chondrocyte-seeded alginate constructs. Cyclic
tension also up-regulated the expression of COL2A1, carti-
lage oligomeric matrix protein (COMP) and Proteoglycan 4
(PRG4), but did not change the expression of SOX9 and
ACAN. Cyclic hydrostatic pressure down-regulated the
expression of MMP13 and COL1A1 and up-regulated
expression of TIMP1 compared to the unloaded controls.
Hydrostatic pressure may slow chondrocyte differentiation
and have a chondroprotective, anti-angiogenic influence on
cartilage tissue. These findings suggested that cyclic
tension activates the RUNX2/MMP13 pathway and increases
the expression of terminal differentiation hypertrophic
markers.150 Bian and colleagues found that dynamic
compressive loading increased the mechanical properties,
as well as the glycosaminoglycan (GAG) and collagen con-
tents of human BMSC-seeded hyaluronic acid hydrogel
constructs in a seeding density dependent manner and was
also shown to significantly reduce the expression of hy-
pertrophic markers and to suppress the degree of calcifi-
cation in MSC-seeded hyaluronic acid hydrogels.151
Low-intensity ultrasound (LUS)was shown to enhance TGF-
b-mediated chondrogenic differentiation of human BMSCs in a
pellet culture system.152 Similarly, Cui and coworkers found
that LUS pretreatment could significantly increase chondro-
genic genes while decreasing hypertrophic genes in rabbit
BMSCs seeded onPGA scaffold; fourweeks after subcutaneous
transplantation into nude mice, the LUS and LUS/TGF groups
were significantly better at forming hyaline cartilage-like
tissue than the non-LUS groups. The development of osteo-
genic phenotypes shown by von Kossa staining was highly
suppressed until four weeks in the LUS groups, along with
compressive strength comparable to the positive control.153
Prevention of chondrogenic hypertrophy 85Potential mechanisms underlying
chondrogenic hypertrophy
Many signaling pathways and biophysical factors have been
involved in the process of chondrogenic hypertrophy, so
understanding these pathways (Fig. 3) will benefit the
control of hypertrophy in cartilage regeneration.
PTHrP/IHH signaling
As one of the key anti-hypertrophy factors, PTHrP functions
by activating protein kinase A (PKA) and, to a lesser extent,
protein kinase C (PKC).154 cAMP-dependent PKA phosphor-
ylates SOX9 and activates protein phosphatase II (PP2A)155
leading to the dephosphorylation of HDAC4 and the inacti-
vation of MEF2C.156 PKC inhibits the activity of p38 MAPK157
reducing MEF2C phosphorylation158 and, ultimately, hy-
pertrophic gene expression.159 PTHrP also interferes with
the calcium pathway by dephosphorylation of calcium/Figure 3 Potential signaling pathways of chondrocyte hypertrop
calcium ion channel signaling, (c): TGF-b/BMP signaling, (d): Wnt s
signaling, and (h): integrin signaling. The main transcription factor
expression of COLII and AGC, and RUNX2 which regulates transcrip
SOX9 was shown to repress RUNX2162 through Nkx3.289 and LEF/TC
each other’s expression.162 Nkx3.2 is induced by PTHrP89 and acts sy
to be the main regulator of RUNX2,15 and drives the expression of
ylation/dephosphorylation. ‘/’ means ‘increase’, ‘T’ means ‘inhicalmodulin (CaM)-dependent protein kinase II (CaMKII)
because endogenous CaMKII activity is up-regulated prior to
hypertrophy; the loss of CaMKII function substantially
blocks the transition from proliferation to hypertrophy.160
In addition, PTHrP blocks hypertrophy by stimulating
Nkx3.289 and preventing RUNX2 expression.89,161 Sonic
Hedgehog (SHH) and BMP signals work in sequence to
establish a positive regulatory loop between SOX9 and
Nkx3.2.162 Interestingly, IHH and PTHrP signaling play
crucial roles in regulating the onset of chondrocyte hyper-
trophy by forming a negative feedback loop, in which IHH
signaling regulates chondrocyte hypertrophy by controlling
PTHrP expression. IHH signaling is also found to promote
chondrocyte hypertrophy of PTHrP independently.163,164Ion channels
Accumulation of cytosolic Ca2þ concentration is indispens-
able to proper chondrogenesis.165 This cytoplasmic Ca2þhy, including but not limited to (a): PTHrP/IHH signaling, (b):
ignaling, (e): MAPK (TGF-a) signaling, (f): HIF signaling, (g) FGF
s regulating hypertrophy are SOX9, which is responsible for the
tion of COL10A1, IHH, MMP13, VEGF, ALP, OC, and OPN genes.
F/b-catenin complex.184,185 Nkx3.2 and SOX9 mutually induce
nergistically with SOX9243 to inhibit RUNX2.56 MEF2C is proposed
the terminal differentiation markers.15 ‘P’ depicts phosphor-
bit’.
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ways. Extracellular Ca2þ can directly pass through ion
channels in the cell membrane or, alternatively, it can
activate G-protein coupled receptors (GPCRs), such as the
calcium-sensing receptor, CaR, which is expressed in
elevated levels in hypertrophic chondrocytes166 that stim-
ulate intracellular Ca2þ release from the endoplasmic re-
ticulum (ER).167 Activation of CaR could increase the
expression of COLX. The Ca2þ release from the ER is regu-
lated by phospholipase C (PLC) activation, prompting hy-
drolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to
inositol 1,4,5-triphosphate (IP3), which triggers the opening
of ER ion-channels (IP3R).168 A series of changes of signaling
pathways are triggered by cytoplasmic calcium via CaM,
CaMKII, and calcineurin.169
Phosphorylation of HDAC4 by CaMKII promotes nuclear
export and prevents nuclear import of HDAC4 with conse-
quent derepression of chondrocyte hypertrophy.170 PTHrP
inhibited the activity of p38 MAPK, which led to an increase
in Bcl-2 activity which was further shown to inhibit IP3R
channel opening.171 Administration of PTHrP or the over-
expression of its receptor abolished the effect of elevated
calcium to increase terminal differentiation markers via
dephosphorylation of CaMKII activity.160 A synergistic rela-
tionship exists between the stimulatory effect of active
CaMKII and RUNX2 on IHH expression.160 Increasing Ca2þ
concentration results in significant up-regulation of Erk1/2
phosphorylation promoting chondrocyte hypertrophy and
mineralization.172
TGF-b/BMP signaling
Hellingman and colleagues found that blocking Smad2/3
after the onset of chondrogenesis resulted in a halt in COLII
production; blocking Smad1/5/8 resulted in decreased
expression of MMP13, COLX, and ALP while allowing COLII
production. Moreover, blocking Smad1/5/8 prevented
mineralization. This finding indicated that, while Smad2/3
is important for continuation of COLII deposition, Smad1/5/
8 phosphorylation is associated with terminal differentia-
tion and mineralization.173 TGF-b-dependent Smad3
signaling pathways present a key role for the SOX9-
dependent transcriptional activation in primary chondro-
genesis174 and also leads to RUNX2 inhibition through
dephosphorylation of HDAC4.175 The Smad2/3 and Smad1/
5/8 pathways can be blocked by Smad7, while only the
Smad1/5/8 pathway can be inhibited by Smad6. Therefore,
hypertrophy can be suppressed by up-regulating the
expression of Smad6.176,177 Smurf1 can suppress terminal
differentiation via blocking the Smad1/5/8 pathway178 and
Smurf2 can decrease chondrogenic differentiation by
blocking the Smad2/3 pathway.179 Thus, endochondral
ossification can be stimulated by overexpression of
Smurf2.180
Wnt signaling
The Wingless/Int (Wnt) signaling, including canonical Wnt
(cWnt) and non-canonical Wnt (ncWnt), is another pathway
involved in regulation of chondrocyte hypertrophy. cWnt
signaling controls the fate of b-catenin via the Frizzledreceptor (FzR).181 In the absence of cWnt, b-catenin is
bound by a degradation complex consisting of glycogen
synthase kinase 3 (GSK3), adenomatous polyposis coli
(APC), AXIN, and casein kinase 1a (CKI) which phosphory-
late b-catenin initiating its ubiquitination and proteosomal
degradation.182 cWnt activation of the FzR and coreceptor
low density lipoprotein receptor-related protein 5 and 6
(LRP5/6) interferes with the degradation complex; b-cat-
enin can translocate to the nucleus where it binds to the
lymphoid enhancer factor (LEF) and T cell factor (TCF)
proteins. The LEF/TCF/b-catenin complex promotes
RUNX2-expression inducing hypertrophy.183 SOX9 inhibits
this signaling through phosphorylation/degradation of b-
catenin.184,185 The inhibition of cWnt leads to an increase in
COL2A1 and ACAN expression but does not affect COL10A1
expression in MSC pellet culture.186 The ncWnts (such as
Wnt5a) exhibit dual functions during chondrogenesis of
MSCs. At early stages, Wnt5a induces chondrogenesis and
hypertrophy through intracellular Ca2þ release via GPCR
activation. Later, it acts as an inhibitor of hypertrophy by
activating the phosphoinositide 3-kinase (PI3K)/protein ki-
nase B (PKB or Akt)-dependent pathway which, in turn,
activates nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB), an inhibitor of RUNX2.187
Gremlin 1 (GREM1), frizzled related protein (FRZB), and
dickkopf 1 homolog (Xenopus laevis) (DKK1) are enriched in
articular cartilage compared with other hyaline cartilage
types and these BMP and cWnt antagonists are important
regulators of articular cartilage homeostasis by preventing
hypertrophic differentiation of chondrocytes.188 GREM1,
FRZB, and DKK1 mRNA expression levels are down-
regulated in osteoarthritis.189,190 FRZB and DKK1 are cWnt
antagonists and GREM1 is a BMP antagonist. GREM1 is also
able to inhibit Wnt signaling via unknown indirect mecha-
nisms and BMP signaling is able to repress Wnt signaling.191
The crosstalk between BMP and cWnt signaling might act as
a feedback loop that balances the activity of both
pathways.190MAPK signaling
MAPKs play a key role in a variety of cellular responses
including proliferation, differentiation, and apoptosis of
cells.192 The Erk1/2 MAPK pathway is activated by growth
factors and the JNK/p38 MAPK pathways are activated by
cellular stress, cytokines, and hypoxia.193,194 Inhibition of
p38 MAPK in hypertrophic chondrocytes by either PTH,
SB203580, or both together leads to a decrease of COL10A1
mRNA and an increase of the expression of prehypertrophic
marker cartilage matrix protein. Therefore, inhibition of
p38 converts a hypertrophic cell phenotype to a pre-
hypertrophic one, thereby preventing precocious chon-
drocyte hypertrophy.157,158
Activation of the Erk1/2 pathway promoted chondrocyte
hypertrophy.79,195 TGF-a, an activator of epidermal growth
factor receptor (EGFR) signaling, was up-regulated in
articular chondrocytes in experimentally induced and
human osteoarthritis; inhibition of MAPK kinase (MEK)/
Erk1/2 could prevent TGF-a-induced deterioration of COLII
and AGC.196 Stimulation of EGFR signaling in articular
chondrocytes by TGF-a resulted in the activation of RhoA/
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p38 MAPK pathways and cartilage degradation. Therefore,
inhibition of p38 MAPK and Erk1/2 is an effective strategy to
minimize hypertrophy in cartilage regeneration.
HIF signaling
Hypoxia inducible factor 1 alpha (HIF-1a), an oxygen-
sensitive transcription factor, was reported to promote
chondrogenesis of MSCs197 in part by activating SOX9 via a
HIF-1a-dependent mechanism.198 Strobel and coauthors
demonstrated that the chondrogenic and anti-catabolic
effect (MMP13) of hypoxia in pellet culture of human
articular chondrocytes disappeared with the addition of a
HIF-1a inhibitor.199 The exact role of HIF-2a in chondro-
genesis is currently undetermined. Hypoxic conditions
enhanced robust chondrogenesis with an up-regulation of
HIF-2a but suppressed COL10A1 in BMSC pellet cultures
regardless of the oxygen tension during BMSC isolation and
propagation.200 Lafont and coworkers found that hypoxia
promoted cartilage matrix synthesis specifically through
HIF-2a-mediated SOX9 induction of key cartilage genes.201
Interestingly, HIF-2a was also reported to enhance pro-
moter activities of COL10A1, MMP13, and VEGFA through
specific binding to the respective hypoxia-responsive ele-
ments and was essential for endochondral ossification of
cultured chondrocytes and embryonic skeletal growth in
mice.202 In addition, HIF-2a caused cartilage destruction by
regulating crucial catabolic genes, such as MMPs, ADAMTS4,
nitric oxide synthase-2 (NOS2), and prostaglandin-
endoperoxide synthase-2 (PTGS2).203
FGF signaling
FGF receptor 3 (FGFR3) is a tyrosine kinase receptor
expressed in proliferating chondrocytes and early hyper-
trophic chondrocytes in the growth plate; its deficiency in
mice resulted in the expansion of both the proliferative
zone (PZ) and hypertrophic zone (HZ), indicating FGFR3
suppresses both proliferation and differentiation.204,205 The
major ligands of FGFR3 in the growth plate include
FGF18206,207 and FGF9.208 Mice lacking FGF18 display
expanded PZ and HZ, similar to FGFR3-null mice. Recently,
Shung and colleagues found that FGFR3 expression
increased SOX9 and decreased b-catenin levels and tran-
scriptional activity in cultured mesenchymal cells. Since
both SOX9 overexpression and b-catenin deletion indepen-
dently block hypertrophic differentiation of chondrocytes,
activation of FGF signaling may inhibit the hypertrophic
differentiation of chondrocytes.
Integrin signaling
The mutual recognition and adhesion between chon-
drocytes and ECM can translate extracellular stimulation
into intracellular cascades via integrin activation.209 The
Rho family of GTPases is a family of small signaling G pro-
teins and a subfamily of the Ras superfamily. Three mem-
bers of the Rho GTPase family, Cdc42, Rac1, and RhoA, are
implicated in the formation of actin cytoskeletal organi-
zation in fibroblasts. Activating the Integrin-Rho signalpathway led to the formation of stress fibers and focal
adhesions and regulated the signal transduction process
between cell membrane receptor and cytoskeleton.210
Xu and coworkers found that TGF-b treated SDSCs illus-
trated the activation of the RhoA/ROCK pathway and
concomitantly induced cytoskeletal reorganization and
gene expression of SOX9, COL2A1, and ACAN.211 RhoA
overexpression in chondrogenic ATDC5 cells resulted in
increased proliferation and a marked delay of hypertrophic
differentiation.212 Overexpression of Rac1/Cdc42 in ATDC5
cells activated the p38 MAPK pathway, which plays a crucial
role in hypertrophy,158 resulting in decreased proliferation
and a marked acceleration of hypertrophic differentia-
tion.81 Integrin a1b1213 and integrin a5b1214 were demon-
strated to induce GTP-bound transglutaminase 2 (TG2)
mobilization to the cell surface, phosphorylation of p38
MAPK, and expression of MEF2C, indicating that blocking
integrin b1, a COLII and COLX binding integrin, is a successful
strategy to suppress COLX expression in chondrocytes.Epigenetic regulation
Many differences in gene expression arise during develop-
ment and are subsequently retained through mitosis. Stable
alterations of this kind are said to be ‘epigenetic’215 because
they are heritable in the short term but do not involve mu-
tations of the DNA itself. Histone (de)acetylation, DNA
methylation, and microRNAs (miRs) are epigenetic events
strongly involved in chondro-specific differentiation.216,217
HDAC4
Up-regulation of HDAC4 increased chondrogenesis as well
as suppressing hypertrophy by inhibiting RUNX2 and
MEF2C.57,102,103,218 CaMKIV induced chondrocyte differen-
tiation through regulation of HDAC4 subcellular relocation,
from the nucleus to the cytoplasm, which resulted in
increased activity of RUNX2 and the transition of chon-
drocytes from the proliferative to the prehypertrophic
stage.219 Nuclear HDAC4 is not tethered in the nucleus, but
instead shuttles between the nucleus and the cytoplasm.
Phosphorylation-induced 14-3-3 binding biases the balance
of nucleo-cytoplasmic shuttling toward the cytoplasm by
inhibiting nuclear import.220 HDAC4 nuclear localization
was enhanced by TGF-b and PTHrP,102,156,218 whereas
increased calcium concentration led to its phosphorylation
and nuclear export.170 In addition to HDAC4, HDAC5, and
HDAC7 suppressed MEF2C and RUNX2, respectively.221,222
MicroRNA 140
MicroRNAs are a class of noncoding regulatory small RNA
about 22 nucleotides (w22 nt) in length that probably
function as antisense regulators of other RNAs and pro-
foundly affect cell proliferation, differentiation, apoptosis,
and individual growth and development.223,224 Previous
studies found reduced miR-140 expression in human osteo-
arthritic cartilage,225,226 which may contribute to the
abnormal gene expression pattern characteristic of osteo-
arthritis. The expression of miR-140 shadows SOX9 expres-
sion,227 and the deletion of SOX9 diminishes miR-140
expression during embryogenesis, indicating that miR-140
is subject to SOX9 regulation in chondrocytes. Transfection
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down-regulated IL-1b-induced ADAMTS5 expression.226,228
Buechli and coworkers demonstrated that miR-140 was
highly expressed in normal equine articular cartilage and
chondrogenically induced equine cord blood-derived MSCs;
miR-140 expression closely paralleled that of the cartilage-
specific transcription factor SOX9 while up-regulation of
miR-140 repressed chemokine (CXC motif) ligand 12
(CXCL12) and ADAMTS5.229
DNA methylation
DNA methylation of mammals occurs in the cytosine of the
CpG dinucleotide via a reaction catalyzed by proteins called
DNA methyltransferases.230 Ezura and coworkers found that
the DNA methylation levels of CpG-rich promoters of genes
related to chondrocyte phenotypes were largely kept low
during chondrogenesis in human SDSCs.231 The findings from
Zimmermann and colleagues indicated that methylation-
based COL10A1 gene silencing is established in cartilage
tissue and human articular chondrocytes. Altered methyl-
ation levels at 2 CpG sites of COL10A1 in MSCs and their
demethylation during chondrogenesis may facilitate induc-
tion of COL10A1 as observed during in vitro chondrogenesis
of MSCs.232 These studies show that chondrogenic differen-
tiation can be regulated by the level of DNA methylation.217
With osteoarthritis, the methylation of MMPs present in
healthy cartilage was lost and the de-methylation led to the
expression of MMP-3/9/13 and ADAMTS4.233,234 The appli-
cation of the nonspecific de-methylating agent 5-aza-deox-
ycytidine on chondrogenic differentiation yielded mixed
results.235 The role of gene silencing through DNA methyl-
ation during chondrogenesis and hypertrophy is still in its
infancy and further study is needed.Conclusion and future perspective
Seed cells, growth factors, and scaffolds are three main
elements of tissue engineering; mechanical stimulation also
has a great impact on differentiation, so strategies to
minimize hypertrophy for cartilage regeneration could be
explored from those aspects.
Great variability in the differential capacity certainly ex-
ists between tissue-specific stemcells,whichmayvarywithin
the same cell type.26,88 For researchers investigating stem
cell-based tissue engineering, it is necessary to choose the
most appropriate type ofMSC naturally suited to the research
goals and objectives. SDSCs have a great capacity for prolif-
eration and chondrogenic differentiation, a small potential
for hypertrophy, and are tissue specific for cartilage reha-
bilitation; to our knowledge, SDSCs are the most appropriate
stem cell source for cartilage engineering and regenera-
tion.27 Chondrogenic differentiation of MSCs is also influ-
enced by specific intervention, such as growth factors and
transduction signals, and the comprehensive environment,
such as co-culture with articular chondrocytes, hypoxia, and
biomechanical stimulation. Recently, culture substrates,
such as decellularized ECM, have received intense attention
in lowering hypertrophic potential during chondrogenic
induction.
In summary, to get adequate, high quality chondrocytes
in vitro, the first challenge that needs to be overcome ishypertrophy of chondrogenic MSCs in cartilage tissue engi-
neering. Understanding a series of signaling pathways and
biophysical factors which have been involved in the process
of chondrocyte hypertrophy will be beneficial to controlling
hypertrophy during cartilage regeneration.
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